Atypical Hemolytic Uremia Syndrome in A Young Adult Male

Atypical hemolytic uremia syndrome (aHUS) is a rare, life-threatening disease, characterized by the same triad of anemia, thrombocytopenia and renal failure as seen in (HUS). It differs its etiology, being caused dysregulation complement pathway rather than Shiga-like toxin-producing Escherichia coli (STEC). Diagnosis usually after exclusion STEC infection also thrombotic thrombocytopenic purpura (TTP). The prognosis aHUS poor, with 50% cases progressing to end-stage disease 25% resulting mortality acute phase. treatment choice plasma exchange which can lower mortality. Monoclonal antibody drugs such eculizumab, suppress dysregulated help prevent mediated kidney injury, but remain prohibitively expensive.